Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

Bibliography

• Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
   PubMed Web of Science ®Google Scholar
• Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol 2012;11:708-19
   PubMed Web of Science ®Google Scholar
• Alevizaki M, Shiraishi A, Rassool FV, et al. The calcitonin-like sequence of the beta CGRP gene. FEBS Lett 1986;206:47-52
   PubMed Web of Science ®Google Scholar
• Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 1997;11:167-239
   PubMed Web of Science ®Google Scholar
• Tippins JR, Di Marzo V, Panico M, et al. Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). Biochem Biophys Res Commun 1986;134:1306-11
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Moller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999;76:176-83
   PubMedGoogle Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003;106:461-70
   PubMed Web of Science ®Google Scholar
• Moskowitz MA. Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. Headache 2008;48:688-90
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev 2005;48:438-56
   PubMed Web of Science ®Google Scholar
• Tajti J, Pardutz A, Vamos E, et al. Migraine is a neuronal disease. J Neural Transm 2011;118:511-24
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Pardutz A, et al. Where does a migraine attack originate? In the brainstem. J Neural Transm 2012;119:557-68
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Villalon CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012;136:319-33
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82
   PubMed Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24
   PubMed Web of Science ®Google Scholar
• Hay DL, Poyner DR, Quirion R. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol Rev 2008;60:143-5
   PubMed Web of Science ®Google Scholar
• Heroux M, Breton B, Hogue M, Bouvier M. Assembly and signaling of CRLR and RAMP1 complexes assessed by BRET. Biochemistry 2007;46:7022-33
   PubMed Web of Science ®Google Scholar
• McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-9
   PubMed Web of Science ®Google Scholar
• Evans BN, Rosenblatt MI, Mnayer LO, et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2000;275:31438-43
   PubMed Web of Science ®Google Scholar
• Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420-3
   PubMed Web of Science ®Google Scholar
• Aiyar N, Rand K, Elshourbagy NA, et al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 1996;271:11325-9
   PubMed Web of Science ®Google Scholar
• Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645-56
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10
   PubMed Web of Science ®Google Scholar
• Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-7
   PubMed Web of Science ®Google Scholar
• Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416-21
   PubMed Web of Science ®Google Scholar
• Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 2010;50:1367-76
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010;30:1443-57
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17:393-406
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014;34:114-25
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807-18
   PubMed Web of Science ®Google Scholar
• Page IH. Serotonin (5-hydroxytryptamine). Physiol Rev 1954;34:563-88
   PubMed Web of Science ®Google Scholar
• Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 1961;19:55-8
   Web of Science ®Google Scholar
• Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989;9(Suppl 9):23-33
   PubMedGoogle Scholar
• Hou M, Kanje M, Longmore J, et al. 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001;909:112-20
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30
   PubMed Web of Science ®Google Scholar
• Cohen ML, Schenck K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 1999;290:935-9
   PubMed Web of Science ®Google Scholar
• Ma QP. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001;12:1589-91
   PubMed Web of Science ®Google Scholar
• Waeber C, Moskowitz MA. [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995;352:263-75
   PubMed Web of Science ®Google Scholar
• Bhalla P, Saxena PR, Sharma HS. Molecular cloning and tissue distribution of mRNA encoding porcine 5-HT7 receptor and its comparison with the structure of other species. Mol Cell Biochem 2002;238:81-8
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010;30:1159-69
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012;13:271-5
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia 2010;30:1170-8
   PubMed Web of Science ®Google Scholar
• Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13
   PubMed Web of Science ®Google Scholar
• Sicuteri F. Dopamine, the second putative protagonist in headache. Headache 1977;17:129-31
   PubMed Web of Science ®Google Scholar
• Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev 1998;78:189-225
   PubMed Web of Science ®Google Scholar
• D’Andrea G, Granella F, Perini F, et al. Platelet levels of dopamine are increased in migraine and cluster headache. Headache 2006;46:585-91
   PubMed Web of Science ®Google Scholar
• Lazarov N, Pilgrim C. Localization of D1 and D2 dopamine receptors in the rat mesencephalic trigeminal nucleus by immunocytochemistry and in situ hybridization. Neurosci Lett 1997;236:83-6
   PubMed Web of Science ®Google Scholar
• Peterfreund RA, Kosofsky BE, Fink JS. Cellular localization of dopamine D2 receptor messenger RNA in the rat trigeminal ganglion. Anesth Analg 1995;81:1181-5
   PubMed Web of Science ®Google Scholar
• Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 1997;49:201-6
   PubMed Web of Science ®Google Scholar
• de Sousa SC, Karwautz A, Wober C, et al. A dopamine D4 receptor exon 3 VNTR allele protecting against migraine without aura. Ann Neurol 2007;61:574-8
   PubMed Web of Science ®Google Scholar
• Fernandez F, Lea RA, Colson NJ, et al. Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci 2006;251:118-23
   PubMed Web of Science ®Google Scholar
• Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-6
   PubMed Web of Science ®Google Scholar
• Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14:27-35
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med 2002;23:141-8
   PubMed Web of Science ®Google Scholar
• Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011;57:475-82; e1
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993;13:124-7
   PubMed Web of Science ®Google Scholar
• Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984;4:85-90
   PubMed Web of Science ®Google Scholar
• Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 2006;46:781-7
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Young WB, Mendizabal JE, et al. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology 2003;60:315-21
   PubMed Web of Science ®Google Scholar
• Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia 2007;27:1308-14
   PubMed Web of Science ®Google Scholar
• Walkembach J, Bruss M, Urban BW, Barann M. Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers. Br J Pharmacol 2005;146:543-52
   PubMed Web of Science ®Google Scholar
• Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989;164:567-74
   PubMed Web of Science ®Google Scholar
• Sundler F, Ekblad E, Hannibal J, et al. Pituitary adenylate cyclase-activating peptide in sensory and autonomic ganglia: localization and regulation. Ann N Y Acad Sci 1996;805:410-26; discussion 27-8
   PubMed Web of Science ®Google Scholar
• Erdling A, Sheykhzade M, Maddahi A, et al. VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides 2013;47:85-92
   PubMed Web of Science ®Google Scholar
• Bourgault S, Vaudry D, Botia B, et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 2008;29:919-32
   PubMed Web of Science ®Google Scholar
• Csati A, Tajti J, Kuris A, et al. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience 2012;202:158-68
   PubMed Web of Science ®Google Scholar
• Uddman R, Tajti J, Hou M, et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002;22:112-16
   PubMed Web of Science ®Google Scholar
• Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 2012;32:140-9
   PubMed Web of Science ®Google Scholar
• Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009;132:16-25
   PubMed Web of Science ®Google Scholar
• Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 2014;137:779-94
   PubMed Web of Science ®Google Scholar
• Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008;28:226-36
   PubMed Web of Science ®Google Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013;33:1085-95
   PubMed Web of Science ®Google Scholar
• Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007;28:1631-9
   PubMed Web of Science ®Google Scholar
• Lerner EA, Iuga AO, Reddy VB. Maxadilan, a PAC1 receptor agonist from sand flies. Peptides 2007;28:1651-4
   PubMed Web of Science ®Google Scholar
• Jansen-Olesen I, Baun M, Amrutkar DV, et al. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides 2014;48:53-64
   PubMed Web of Science ®Google Scholar
• Martinez F, Castillo J, Rodriguez JR, et al. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 1993;13:89-93
   PubMed Web of Science ®Google Scholar
• Rajda C, Tajti J, Komoroczy R, et al. Amino acids in the saliva of patients with migraine. Headache 1999;39:644-9
   PubMedGoogle Scholar
• Bereiter DA, Benetti AP. Excitatory amino release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat. Pain 1996;67:451-9
   PubMed Web of Science ®Google Scholar
• Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache 2006;46(Suppl 1):S39-44
   PubMed Web of Science ®Google Scholar
• Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005;179:4-29
   PubMed Web of Science ®Google Scholar
• Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 2000;97:4926-31
   PubMed Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742-55
   PubMed Web of Science ®Google Scholar
• Tallaksen-Greene SJ, Young AB, Penney JB, Beitz AJ. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett 1992;141:79-83
   PubMed Web of Science ®Google Scholar
• Watanabe M, Mishina M, Inoue Y. Distinct gene expression of the N-methyl-D-aspartate receptor channel subunit in peripheral neurons of the mouse sensory ganglia and adrenal gland. Neurosci Lett 1994;165:183-6
   PubMed Web of Science ®Google Scholar
• Liu XB. Subcellular distribution of AMPA and NMDA receptor subunit immunoreactivity in ventral posterior and reticular nuclei of rat and cat thalamus. J Comp Neurol 1997;388:587-602
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-9
   PubMed Web of Science ®Google Scholar
• Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994;117(Pt 1):199-210
   PubMed Web of Science ®Google Scholar
• Smith JM, Bradley DP, James MF, Huang CL. Physiological studies of cortical spreading depression. Biol Rev Camb Philos Soc 2006;81:457-81
   PubMed Web of Science ®Google Scholar
• Peeters M, Gunthorpe MJ, Strijbos PJ, et al. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther 2007;321:564-72
   PubMed Web of Science ®Google Scholar
• Classey JD, Knight YE, Goadsby PJ. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res 2001;907:117-24
   PubMed Web of Science ®Google Scholar
• Willette RN, Lysko PG, Sauermelch CF. A comparison of (+)SK&F 10047 and MK-801 on cortical spreading depression. Brain Res 1994;648:347-51
   PubMed Web of Science ®Google Scholar
• Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 2009;18:789-803
   PubMed Web of Science ®Google Scholar
• Hattori Y, Watanabe M, Iwabe T, et al. Administration of MK-801 decreases c-Fos expression in the trigeminal sensory nuclear complex but increases it in the midbrain during experimental movement of rat molars. Brain Res 2004;1021:183-91
   PubMed Web of Science ®Google Scholar
• Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-60
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia 2001;21:96-101
   PubMed Web of Science ®Google Scholar
• Bigal M, Rapoport A, Sheftell F, et al. Memantine in the preventive treatment of refractory migraine. Headache 2008;48:1337-42
   PubMed Web of Science ®Google Scholar
• Obrenovitch TP, Zilkha E. Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex. Br J Pharmacol 1996;117:931-7
   PubMed Web of Science ®Google Scholar
• Kaube H, Herzog J, Kaufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000;55:139-41
   PubMed Web of Science ®Google Scholar
• Vecsei L. Kynurenines in the brain. From experiments to clinics. Nova; New York: 2005
   Google Scholar
• Gal EM, Sherman AD. Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem 1978;30:607-13
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Cullen KM, Lim CK, et al. Characterization of the kynurenine pathway in human neurons. J Neurosci 2007;27:12884-92
   PubMed Web of Science ®Google Scholar
• Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989;52:1319-28
   PubMed Web of Science ®Google Scholar
• Prescott C, Weeks AM, Staley KJ, Partin KM. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 2006;402:108-12
   PubMed Web of Science ®Google Scholar
• Rozsa E, Robotka H, Vecsei L, Toldi J. The Janus-face kynurenic acid. J Neural Transm 2008;115:1087-91
   PubMed Web of Science ®Google Scholar
• Chauvel V, Vamos E, Pardutz A, et al. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol 2012;236:207-14
   PubMed Web of Science ®Google Scholar
• Olah G, Heredi J, Menyhart A, et al. Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability. Drug Des Devel Ther 2013;7:981-7
   PubMed Web of Science ®Google Scholar
• Knyihar-Csillik E, Toldi J, Mihaly A, et al. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm 2007;114:417-21
   PubMed Web of Science ®Google Scholar
• Vamos E, Fejes A, Koch J, et al. Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. Headache 2010;50:834-43
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014;28:389-99
   PubMed Web of Science ®Google Scholar
• Peroutka SJ. Calcitonin gene-related Peptide targeted immunotherapy for migraine: progress and challenges in treating headache. BioDrugs 2014;28:237-44
   PubMed Web of Science ®Google Scholar
• Vollbracht S, Rapoport AM. New treatments for headache. Neurol Sci 2014;35(Suppl 1):89-97
   PubMed Web of Science ®Google Scholar
• Warfvinge K, Edvinsson L. Pearls and pitfalls in neural CGRP immunohistochemistry. Cephalalgia 2013;33:593-603
   PubMed Web of Science ®Google Scholar
• Lucaites VL, Krushinski JH, Schaus JM, et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol 2005;371:178-84
   PubMed Web of Science ®Google Scholar